Published online Feb 26, 2020. doi: 10.12998/wjcc.v8.i4.658
Peer-review started: January 2, 2020
First decision: January 19, 2020
Revised: January 20, 2020
Accepted: February 15, 2020
Article in press: February 15, 2020
Published online: February 26, 2020
Processing time: 55 Days and 8.4 Hours
Gastric signet ring cell carcinoma (GSRCC) has the features of high invasiveness, rapid progression, and resistance to chemotherapy. However, systematic analyses of mRNAs have not yet been performed.
The exploration of the molecular mechanism of GSRCC is important to improve the recognition of GSRCC and find the effective therapeutics to raise the survival rate of patients.
Transcriptome sequencing and comprehensive analysis were performed to identify key mRNAs and signaling pathways in GSRCC.
A transcriptome analysis of two GSRCC and two non-GSRCC samples was performed. Differentially expressed mRNAs and pathways were identified. The interactive relationships among the differential genes were mapped with the STRING database.
The enriched KEGG and PANTHER pathways for the differential genes included immune response pathways, metabolic pathways, and metastasis-associated pathways. MAGEA2, MAGEA2B, MAGEA3, MAGEA4, MAGEA6, MUC13, GUCA2A, FFAR4, REG1A, and REG1B were identified as hub genes in the protein-protein interaction network. The expression levels of MAGEA2, MAGEA3, MAGEA4, MAGEA6, and REG1B showed potential clinical value.
The potential key genes and pathways of GSRCC have been identified. These hub genes and pathways could be diagnostic markers and therapeutic targets for GSRCC.
MAGE-A family as a CTA family member may be the potential targets for GSRCC. More research should be conducted for exploration of the mechanisms involved.